查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1424394

1型多腺體自體自體免疫症候群的全球市場：依診斷、治療、劑型、給藥途徑、發病年齡、分銷管道和地區

Global Autoimmune Polyglandular Syndrome Type 1 Market, By Diagnosis, By Treatment, By Dosage Form, By Route of Administration, By Age of Onset, By Distribution Channel, By Geography
出版日期: | 出版商: Coherent Market Insights | 英文 172 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

全球多腺體自體自體免疫症候群 1 型市場規模預計將從 2023 年的 2.57 億美元增至 2030 年的 3.179 億美元，預測期內複合年成長率為 3.1%。

報告範圍 報告詳情
基準年 2022年 2023/2024年市場規模 2.57 億美元
實際資料 2018-2021 預測期 2023-2030
預測期間 2023/2024 至 2030/2031 年複合年成長率： 3.10% 2030/2031 年預測值 3.179 億美元
圖 1. 1 型多腺體自體免疫症候群的全球市場佔有率(%)，按地區分類，2023 年
全球自體免疫多腺體症候群 1 型市場-IMG1

多腺體自體自體免疫症候群1型（APS1），也稱為自體自體免疫多內分泌疾病-安迪氏症-外胚層營養不良症（APECED），是一種多內分泌腺疾病，包括腎上腺、副甲狀腺、性腺和其他組織，是一種罕見的罕見疾病。由自體免疫破壞引起的多系統疾病。 APS1 是 AIRE 基因（自體免疫調節因子）突變的結果，該基因控制組織特異性基因的表達並促進中樞耐受誘導。 AIRE 功能的喪失會導致免疫耐受性失敗並引發多器官自體自體免疫攻擊。 APS1 的常見臨床特徵包括副甲狀腺功能低下、原發性甲狀旁腺功能低下症、慢性皮膚黏膜念珠菌症病和性腺功能不全。多系統受累的早期發病和嚴重程度需要對 APS1 患者進行終身管理和監測。

市場動態：

由於全球 APS1 盛行率不斷上升，預計全球 1 型多腺體自體自體免疫症候群市場將呈現利潤豐厚的成長機會。針對高風險族群的基因篩檢計畫正在提高早期診斷率。越來越多的研究闡明免疫疾病機制和開發新型耐受誘導療法也正在推動市場成長。然而，缺乏核准的標靶藥物和有限的治療選擇繼續限制市場。同時，提高人們對罕見疾病的認知並專注於開發新生技藥品的努力有可能創造有吸引力的機會。作為一種罕見疾病，APS-1 可能會受益於孤兒藥指定和鼓勵研究和開發的激勵措施。正在進行的研究旨在提高我們對潛在機制的理解，並實現更有針對性和有效的治療。然而，患者數量有限給大規模臨床試驗和藥物開發帶來了挑戰。

製藥公司、研究機構和患者支持組織之間的合作對於推進 APS-1 的研究和改善受這種複雜自體自體免疫症候群影響的人們的生活品質至關重要。市場動態受到醫學進步和支持罕見疾病治療的監管環境的影響。

本研究的主要特點

本報告對全球多腺體自體自體免疫症候群1型市場進行了詳細分析，並介紹了以2022年為基準年的預測期（2023-2030）的市場規模和復合年成長率。

它還揭示了各個細分市場的潛在商機，並為該市場說明了一系列有吸引力的投資提案。

它還提供了有關市場促進因素、限制因素、機會、新產品發布和核准、市場趨勢、區域前景、主要企業採取的競爭策略等的主要考察。

根據公司亮點、產品系列、主要成就、財務績效和策略等參數，對全球 1 型自體免疫腺體自體免疫症候群市場的主要企業進行了分析。

該報告的見解將幫助行銷人員和經營團隊高層就未來的產品發布、升級、市場擴張和行銷策略負責人明智的決策。

本研究報告針對該產業的各個相關人員，如投資者、供應商、產品製造商、經銷商、新參與企業和財務分析師。

透過用於分析全球多腺體自體自體免疫症候群 1 型市場的各種策略矩陣，將有助於相關人員做出決策。

目錄

第1章 研究目的與前提

  • 研究目標
  • 先決條件
  • 簡稱

第2章 市場展望

  • 報告說明
    • 市場定義和範圍
  • 執行摘要
  • Coherent Opportunity Map（COM）

第3章市場動態、法規及趨勢分析

  • 市場動態
  • 影響分析
  • 主要亮點
  • 監管場景
  • 服務交付組合
  • PEST分析
  • 波特的分析
  • 併購場景
  • 管道分析

第4章全球多腺體自體自體免疫症候群 1 型市場 –冠狀病毒(COVID-19) 大流行的影響

  • 新型冠狀病毒感染疾病（COVID-19）的流行病學
  • 供需面分析
  • 經濟影響

第 5 章 2018-2030 年全球多腺體自體自體免疫症候群 1 型市場（依診斷）

  • 血清自體自體免疫篩檢
  • 終末器官功能檢測
  • 驗血

第 6 章 2018-2030 年全球多腺體自體自體免疫症候群 1 型市場（依治療）

  • 藥品
  • 抗真菌劑
  • Fluconazole
  • Itraconazole
  • 骨化三醇
  • 皮質類固醇
  • 其他（荷爾蒙替代療法等）

第7章全球多腺體自體自體免疫症候群1型市場，按劑型，2018-2030

  • 錠劑
  • 膠囊
  • 其他

第 8 章全球多腺體自體自體免疫症候群 1 型市場，依給藥途徑，2018-2030 年

  • 口服
  • 其他

第 9 章 2018-2030 年全球多腺體自體自體免疫症候群 1 型市場（依發病年齡）

  • 孩子
  • 成人
  • 青春期

第10章全球多腺體自體免疫症候群1型市場，依通路，2018-2030年

  • 醫院藥房
  • 零售藥房
  • 網路藥房

第11章全球多腺體自體免疫綜合症 1 型市場，按地區，2018-2030

  • 北美洲
  • 美國
  • 加拿大
  • 歐洲
  • 德國
  • 英國
  • 西班牙
  • 法國
  • 義大利
  • 俄羅斯
  • 其他歐洲國家
  • 亞太地區
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國
  • ASEAN
  • 其他亞太地區
  • 拉丁美洲
  • 巴西
  • 阿根廷
  • 墨西哥
  • 其他拉丁美洲
  • 中東
  • 海灣合作理事會國家
  • 以色列
  • 其他中東地區
  • 非洲
  • 北非
  • 中部非洲
  • 南非

第12章競爭形勢

  • Pfizer Inc.
    • Product & Service Portfolio
  • GlaxoSmithKline plc
  • Novartis AG
  • Mylan NV
  • Teva Pharmaceutical Industries Ltd.
  • Sanofi
  • Hoffmann-La Roche Ltd.
  • Zydus Cadila
  • Lupin
  • Amneal Pharmaceuticals LLC.
  • Cipla Inc.
  • Aurobindo Pharma
  • Glenmark Pharmaceuticals Limited
  • Eli Lilly and Company
  • Sun Pharmaceutical Industries Ltd.
  • Allergan
  • Bristol-Myers Squibb Company
  • Takeda Pharmaceutical Company Limited
  • Abbott
  • LEO Pharma A/S

第13章

  • 調查方法
  • 關於出版商
簡介目錄
Product Code: CMI6538

The global autoimmune polyglandular syndrome type 1 market size is expected to reach US$ 317.9 Mn by 2030, from US$ 257 Mn in 2023, exhibiting a CAGR of 3.1% during the forecast period.

Report Coverage Report Details
Base Year: 2022 Market Size in 2023/2024: US$ 257 Mn
Historical Data for: 2018 to 2021 Forecast Period: 2023 - 2030
Forecast Period 2023/2024 to 2030/2031 CAGR: 3.10% 2030/2031 Value Projection: US$ 317.9 Mn
Figure 1. Global Autoimmune Polyglandular Syndrome Type 1 Market Share (%), By Region, 2023
Global Autoimmune Polyglandular Syndrome Type 1 Market - IMG1

Autoimmune polyglandular syndrome type 1 (APS1), also known as autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED), is a rare multisystem disorder caused by the autoimmune destruction of several endocrine glands like the adrenals, parathyroid glands, gonads, and other tissues. APS1 results from mutations in the AIRE gene (autoimmune regulator), which regulates the expression of tissue-specific genes and promotes central tolerance induction. Loss of function of AIRE leads to failures in immune tolerance, leading to autoimmune attacks on multiple organs. Common clinical features of APS1 include hypoparathyroidism, primary adrenal insufficiency, chronic mucocutaneous candidiasis, and gonadal failure. Early onset and severity of multiorgan involvement require lifelong management and monitoring of APS1 patients.

Market Dynamics:

The global autoimmune polyglandular syndrome type 1 market is projected to witness lucrative growth opportunities owing to rising APS1 disease prevalence worldwide. Genetic screening programs for high-risk ethnic populations are driving the early diagnosis rate. Increasing research into understanding immunological disease mechanisms and developing novel tolerance-inducing therapies is also fueling market growth. However, a lack of approved targeted drugs and limited treatment options continue to hamper the market. Meanwhile, initiatives to enhance rare disease awareness and focus on developing new biologics hold potential to create attractive opportunities. As a rare disease, APS-1 may benefit from orphan drug designations and incentives to encourage research and development. Ongoing research aims to deepen our understanding of the underlying mechanisms, allowing for more targeted and effective treatments. However, the limited patient population poses challenges for large-scale clinical trials and drug development.

Collaboration between pharmaceutical companies, research institutions, and patient advocacy groups is crucial for advancing APS-1 research and improving the quality of life for individuals affected by this complex autoimmune syndrome. The market dynamics are influenced by both medical advancements and the regulatory landscape supporting rare disease treatments.

Key features of the study:

This report provides in-depth analysis of the global autoimmune polyglandular syndrome type 1 market, and provides market size (US$ Million) and compound annual growth rate (CAGR%) for the forecast period (2023-2030), considering 2022 as the base year

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market

This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players

It profiles key players in the global autoimmune polyglandular syndrome type 1 market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies

Key companies covered as a part of this study include Pfizer Inc., GlaxoSmithKline plc, Novartis AG, Mylan N.V., Teva Pharmaceutical Industries Ltd., Sanofi, F. Hoffmann-La Roche Ltd., Zydus Cadila, Lupin, Amneal Pharmaceuticals LLC., Cipla Inc., Aurobindo Pharma, Glenmark Pharmaceuticals Limited, Eli Lilly and Company, Sun Pharmaceutical Industries Ltd., Allergan, Bristol-Myers Squibb Company, Takeda Pharmaceutical Company Limited, Abbott, and LEO Pharma A/S.

Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics

The global autoimmune polyglandular syndrome type 1 market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global autoimmune polyglandular syndrome type 1 market

Detailed Segmentation:

  • By Diagnosis
    • Serum Autoimmune Screen
    • End-organ Function Tests
    • Blood Tests
  • By Treatment
    • Medication
    • Antifungal Agents
    • Fluconazole
    • Itraconazole
    • Calcitriol
    • Corticosteroids
    • Others (Hormone Replacement Therapy, etc.)
  • By Dosage Form
    • Tablet
    • Capsule
    • Others
  • By Route of Administration
    • Oral
    • Others
  • By Age of Onset
    • Childhood
    • Adult
    • Adolescent
  • By Distribution Channel
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • By Region
    • North America
    • Europe
    • Asia Pacific
    • Latin America
    • Middle East
    • Africa
  • Key Players:
    • Pfizer Inc.
    • GlaxoSmithKline plc
    • Novartis AG
    • Mylan N.V.
    • Teva Pharmaceutical Industries Ltd.
    • Sanofi
    • F.Hoffmann-La Roche Ltd.
    • Zydus Cadila
    • Lupin
    • Amneal Pharmaceuticals LLC.
    • Cipla Inc.
    • Aurobindo Pharma
    • Glenmark Pharmaceuticals Limited
    • Eli Lilly and Company
    • Sun Pharmaceutical Industries Ltd.
    • Allergan
    • Bristol-Myers Squibb Company
    • Takeda Pharmaceutical Company Limited
    • Abbott
    • LEO Pharma A/S

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Global Autoimmune Polyglandular Syndrome Type 1 Market, By Diagnosis
    • Global Autoimmune Polyglandular Syndrome Type 1 Market, By Treatment
    • Global Autoimmune Polyglandular Syndrome Type 1 Market, By Dosage Form
    • Global Autoimmune Polyglandular Syndrome Type 1 Market, By Route of Administration
    • Global Autoimmune Polyglandular Syndrome Type 1 Market, By Age of Onset
    • Global Autoimmune Polyglandular Syndrome Type 1 Market, By Distribution Channel
    • Global Autoimmune Polyglandular Syndrome Type 1 Market, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Increased incidence of autoimmune disorders
    • Growing Genetic Research Insights
  • Impact Analysis
  • Key Highlights
  • Regulatory Scenario
  • Service offering Portfolio
  • PEST Analysis
  • PORTER's Analysis
  • Merger and Acquisition Scenario
  • Pipeline Analysis

4. Global Autoimmune Polyglandular Syndrome Type 1 Market- Impact of Coronavirus (COVID-19) Pandemic

  • COVID-19 Epidemiology
  • Supply Side and Demand Side Analysis
  • Economic Impact

5. Global Autoimmune Polyglandular Syndrome Type 1 Market, By Diagnosis, 2018-2030, (US$ Mn)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2019 - 2030
    • Segment Trends
  • Serum Autoimmune Screen
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Mn)
  • End-organ Function Tests
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Mn)
  • Blood Tests
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Mn)

6. Global Autoimmune Polyglandular Syndrome Type 1 Market, By Treatment, 2018-2030, (US$ Mn)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2019 - 2030
    • Segment Trends
  • Medication
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Mn)
  • Antifungal Agents
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Mn)
  • Fluconazole
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Mn)
  • Itraconazole
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Mn)
  • Calcitriol
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Mn)
  • Corticosteroids
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Mn)
  • Others (Hormone Replacement Therapy, etc.)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Mn)

7. Global Autoimmune Polyglandular Syndrome Type 1 Market, By Dosage Form, 2018-2030, (US$ Mn)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2019 - 2030
    • Segment Trends
  • Tablet
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Mn)
  • Capsule
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Mn)
  • Others
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Mn)

8. Global Autoimmune Polyglandular Syndrome Type 1 Market, By Route of Administration, 2018-2030, (US$ Mn)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2019 - 2030
    • Segment Trends
  • Oral
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Mn)
  • Others
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Mn)

9. Global Autoimmune Polyglandular Syndrome Type 1 Market, By Age of Onset, 2018-2030, (US$ Mn)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2019 - 2030
    • Segment Trends
  • Childhood
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Mn)
  • Adult
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Mn)
  • Adolescent
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Mn)

10. Global Autoimmune Polyglandular Syndrome Type 1 Market, By Distribution Channel, 2018-2030, (US$ Mn)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2019 - 2030
    • Segment Trends
  • Hospital Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Mn)
  • Retail Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Mn)
  • Online Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Mn)

11. Global Autoimmune Polyglandular Syndrome Type 1 Market, By Region, 2018-2030, (US$ Mn)

  • Introduction
    • Market Share Analysis, By Country, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, For Country 2019 -2030
    • Country Trends
  • North America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Diagnosis, 2018-2030,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2018-2030,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Dosage Form, 2018-2030,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018-2030,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Age of Onset, 2018-2030,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030,(US$ Mn)
  • U.S.
  • Canada
  • Europe
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Diagnosis, 2018-2030,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2018-2030,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Dosage Form, 2018-2030,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018-2030,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Age of Onset, 2018-2030,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030,(US$ Mn)
  • Germany
  • U.K.
  • Spain
  • France
  • Italy
  • Russia
  • Rest of Europe
  • Asia Pacific
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Diagnosis, 2018-2030,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2018-2030,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Dosage Form, 2018-2030,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018-2030,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Age of Onset, 2018-2030,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030,(US$ Mn)
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Latin America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Diagnosis, 2018-2030,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2018-2030,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Dosage Form, 2018-2030,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018-2030,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Age of Onset, 2018-2030,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030,(US$ Mn)
  • Brazil
  • Argentina
  • Mexico
  • Rest of Latin America
  • Middle East
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Diagnosis, 2018-2030,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2018-2030,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Dosage Form, 2018-2030,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018-2030,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Age of Onset, 2018-2030,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030,(US$ Mn)
  • GCC Countries
  • Israel
  • Rest of Middle East
  • Africa
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Diagnosis, 2018-2030,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2018-2030,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Dosage Form, 2018-2030,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018-2030,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Age of Onset, 2018-2030,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030,(US$ Mn)
  • North Africa
  • Central Africa
  • South Africa

12. Competitive Landscape

  • Pfizer Inc.
    • Company Highlights
    • Product & Service Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • GlaxoSmithKline plc
  • Novartis AG
  • Mylan N.V.
  • Teva Pharmaceutical Industries Ltd.
  • Sanofi
  • Hoffmann-La Roche Ltd.
  • Zydus Cadila
  • Lupin
  • Amneal Pharmaceuticals LLC.
  • Cipla Inc.
  • Aurobindo Pharma
  • Glenmark Pharmaceuticals Limited
  • Eli Lilly and Company
  • Sun Pharmaceutical Industries Ltd.
  • Allergan
  • Bristol-Myers Squibb Company
  • Takeda Pharmaceutical Company Limited
  • Abbott
  • LEO Pharma A/S
  • Analyst Views

13. Section

  • Research Methodology
  • About us